Sanarentero LLC
Pearland, TX
- UEI
- VBXLD6X8ZJB4
- CAGE
- 8FDN1
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 514 N Elder Grove Dr, Pearland, TX 77584, USA
- Website
- sanarentero.com
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Vedanta Biosciences, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Nexilico, Inc. | Danville, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Osel, Inc. | Mountain View, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Siolta Therapeutics Inc. | San Carlos, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Sanarentero LLC is a women-owned early-stage company that aims to develop technologies to prevent and treat gut diseases and disorders, as well as chemotherapy-induced gastrointestinal toxicities. They focus on improving lower gastrointestinal health by addressing gut microbiome dysbiosis and gastrointestinal toxicities using bioengineered live biotherapeutic products.
Through federal grant awards from the National Institutes of Health (NIH), Sanarentero LLC has been developing novel drug detoxifying bacteria (DDB) as a live biotherapeutic product to detoxify gut-toxic drugs causing chemotherapy-induced diarrhea in cancer patients. One project involved introducing a genetic biocontainment switch into DDB to improve its safety profile and aid regulatory approval. Another project aimed to develop DDB for effectively glycosylating SN-38 to alleviate severe delayed-onset diarrhea caused by irinotecan chemotherapy. Sanarentero has also received a grant from the National Center for Complementary and Integrative Health to develop a novel herbal therapy for preventing irinotecan-induced severe delayed-onset diarrhea. The grants encompass activities such as bioengineering bacteria, developing colon-targeted delivery systems, evaluating safety and efficacy in animal models, and conducting market research and commercialization strategies for these live biotherapeutic products.
Quick answers
Is Sanarentero LLC registered in SAM.gov?
Yes. Sanarentero LLC's SAM.gov registration is active through September 16, 2027.
What is Sanarentero LLC's most recent federal award?
Sanarentero LLC's most recent federal grant award is Genetic biocontainment switch to improve the safety of drug detoxifying bacteria in preventing chemotherapy-induced… (R41CA275454), from National Cancer Institute (NIH), on April 1, 2023.
On GovTribe
See Sanarentero LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors